Storia in 3 fonti

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.

Raccontata da

endpoints.news

benzinga.com

biopharmadive.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 g fa

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Neumora Therapeutics discontinued navacaprant after Phase 3 depression trials failed statistical significance (p=0.813, p=0.480). The 35% workforce cut and $10M annualized savings extend runway to Q3 2027, signaling biotech cash pressure and strategic focus shift to Alzheimer's and schizophrenia candidates.

originale

endpoints.news2 g fa

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.

Leggi questa versione →

Timeline cronologica

lunedì 15 giugno 2026·endpoints.news
Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
lunedì 15 giugno 2026·benzinga.com
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Confronto fonti

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Timeline cronologica

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Neumora depression drug fails; EnGene to cut 50% of staff

Neumora depression drug fails; EnGene to cut 50% of staff